ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1063

Role of Mitochondrial-Bound HK2 in Rheumatoid Arthritis Fibroblast-like Synoviocytes

Patricia Oliveira1, Marta Fernandez Bustmanate2, Ricard Garcia Carbonell3, Elsa Sanchez-Lopez4, Teresina Laragione5, Percio S. Gulko6, Gary S. Firestein7, Anne N Murphy3, Shigeki Miyamoto8 and Monica Guma7,9, 1Medicine, UCSD, San Diego, CA, 2Medicine, UCSD, La Jolla, CA, 3Pharmacology, UCSD, San Diego, CA, 4Department of Pharmacology, School of Medicine. UCSD., La Jolla, CA, 5Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 6Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 7Medicine, University of California San Diego, La Jolla, CA, 8Pharmacology, UCSD, La Jolla, CA, 9Medicine, Autonomous University of Barcelona, Bellatera, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, mitochondria and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hexokinases (HKs) catalyze the first step in glucose metabolism. HK2 constitutes the principal inducible isoform with a restricted distribution in normal adult tissues. Fibroblast-like synoviocytes (FLS) are a key component of rheumatoid arthritis (RA) invasive synovium, and display unique aggressive features, including increased migration and invasion. We have recently showed a critical role of glucose metabolism and specifically of HK2 in RA FLS phenotype. Of interest, HK2 localizes not only in the cytosol but also at mitochondria and protects mitochondria against apoptosis. We hypothesize that mitochondrial-bound HK2 is key regulator of RA FLS phenotype.

Methods: HK2 localization at baseline and after RA FLS activation with platelet derived growth factor (PDGF, 10ng/ml) was evaluated by cell fractionation and western blot (WB), and confocal microscopy. RA FLS were infected with GFP, full-length (FL)-HK2 or HK2 lacking its mitochondrial binding motif (HK2ΔN) expressing adenovirus (ad). RA FLS were also incubated with metiljasmonate (MJ, 2.5mM), which dissociates HK2 from mitochondria. FLS function in medium and PDGF stimulated cells was evaluated by measuring 1) migration of cultured FLS monolayers (scratch assay); 2) in vitro invasion assay using matrigel. For arthritis experiments, mice were injected with K/BxN sera on day 0. MJ (25mg/kg) was injected daily i.p. beginning on day 0 after serum administration or starting at the peak of arthritis (from day 5). Clinical arthritis scores were serially assessed. Joint histology was evaluated using a semiquantitative scoring system.

Results: 30 minutes after PDGF stimulation, cell fractionation and confocal microscopy revealed that PDGF induced the translocation of HK2 to the mitochondrial fraction. Overexpression of the HK2 mutant reversed the invasive phenotype induced by full-length HK2 after PDGF stimualtion, and also FLS migration rate, GFP-ad: 101.2 ±12.69; FL-HK2-ad: 135.7±38.88; HK2ΔN-ad 112.6±35.72 (FL-HK2-ad vs. HK2ΔN-ad: p<0.01). MJ treatment also significantly reduced RA FLS invasion from 46.79±8,961 to 22.45±7.48 (p<0.001) and migration rate from 253±14 to 152±6 (p<0.001) after PDGF stimulation. Finally, MJ treatment significantly decreased arthritis severity. Day 10 scores were 4.8±0.9 and 1.2±0.58 (P<0.01) for vehicle and MJ-treated mice respectively, when mice were treated from day 0 after serum administration, and 12.5±0.5 and 9.2±0.663 (p<0.05) for vehicle and MJ-treated mice when mice were treated from day 5. Joint histology scores for vehicle and MJ-treated mice from day 0 were: for inflammation 0.9±0.821 and 0.4±0.42 (p<0.05), bone erosion scores were 1.5±0.61 and 0.3±0.45 (p<0.01), and cartilage damage scores were 1.9±0.42 and 0.3±0.45 (p<0.01), respectively.

Conclusion: Our results suggest that mitochondrial HK2 is key regulator of aggressive FLS phenotype, which contributes to joint destruction in RA. Targeting HK2, as an isoform-specific contributor to RA FLS phenotype, offers a safer approach than global glycolysis inhibition. Other possible strategy to improve selectivity would be to target HK2 binding to the mitochondria.


Disclosure: P. Oliveira, None; M. Fernandez Bustmanate, None; R. Garcia Carbonell, None; E. Sanchez-Lopez, None; T. Laragione, None; P. S. Gulko, None; G. S. Firestein, None; A. N. Murphy, None; S. Miyamoto, None; M. Guma, None.

To cite this abstract in AMA style:

Oliveira P, Fernandez Bustmanate M, Garcia Carbonell R, Sanchez-Lopez E, Laragione T, Gulko PS, Firestein GS, Murphy AN, Miyamoto S, Guma M. Role of Mitochondrial-Bound HK2 in Rheumatoid Arthritis Fibroblast-like Synoviocytes [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/role-of-mitochondrial-bound-hk2-in-rheumatoid-arthritis-fibroblast-like-synoviocytes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-mitochondrial-bound-hk2-in-rheumatoid-arthritis-fibroblast-like-synoviocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology